secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001437749-25-028604
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech accelerates Phase 3 AML trial recruitment; targets 45 subjects for Q4 2025 unblinding
--------------------------------------------------------------------------------

- 13 subjects recruited (10 dosed); target of 20 by end of September 2025.
- Expanding to 8 new active sites in September (Spain, Georgia, Poland, Romania, Italy, Lithuania, US) for total 20.
- On track to recruit 45th subject in Q4 2025 for first unblinding of efficacy and safety data.
- Expects to conclude Part A (75–90 subjects) in first half 2026, then commence Part B (~220 subjects).
- CEO cites operational efficiency and investigator enthusiasm; over 30 active sites expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925028604/0001437749-25-028604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925028604/mbrx20250908c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-028604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer